Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome

Deng-Ho Yang 1,2,3, Yu-Hsun Wang 4, Lung-Fa Pan 1,5 and James Cheng-Chung Wei 6,7,*

1 Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Taichung Armed-Forces General Hospital, Taichung 411, Taiwan; deng6263@ms71.hinet.net (D.-H.Y.); lung-fa@803.org.tw (L.-F.P.)
2 Department of Medical Laboratory Science and Biotechnology, Central Taiwan University of Science and Technology, Taichung 406, Taiwan
3 Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
4 Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan; cshe731@csh.org.tw
5 Graduate Institute of Radiological Science, Central Taiwan University of Science and Technology, Taichung 406, Taiwan
6 Department of Rheumatology & Immunology, Chung Shan Medical University Hospital, Taichung 402, Taiwan
7 Institute of Medicine, Chung Shan Medical University, Graduate Institute of Integrated Medicine, China Medical University, Taichung 402, Taiwan
* Correspondence: jccwei@gmail.com; Tel.: +886-4-24739595 (ext. 34718)

Received: 30 September 2020; Accepted: 25 October 2020; Published: 28 October 2020

Abstract: Sjögren’s syndrome (SS) is a chronic systemic inflammation disease with clinical presentation of dry eye, dry mouth, and polyarthralgia. Active inflammation is associated with an increased risk of associated arterial stiffness or subclinical atherosclerosis-related cardiovascular events. We used the longitudinal health insurance database of Taiwan, which includes one million participants, to evaluate the relationship between the clinical medication of hydroxychloroquine (HCQ) and the development of coronary artery disease (CAD). In total, 1674 patients with SS receiving HCQ medication were included after exclusion for previous CAD. Altogether, 1142 SS patients were included for evaluation after follow-up for more than one year. After adjusting for age, gender, medications, and chronic comorbidities, a significantly decreased hazard ratio (HR) for developing CAD was found among SS patients with higher medication possession ratio (MPR) of HCQ (HR = 0.49, 95% confidence interval, CI: 0.26–0.94) when compared with low MPR of HCQ. A low HR for CAD was observed in SS patients with a high cumulative dose of at least 100,267 mg of HCQ (HR = 0.25, 95% CI: 0.09–0.66). Long-term HCQ therapy may decrease the HR of CAD in SS patients. The significant cardiovascular protective effect of HCQ therapy was observed in our study.

Keywords: Sjögren’s syndrome; hydroxychloroquine; inflammation; coronary artery disease; cardiovascular event; autoimmune

1. Introduction

Sjögren’s syndrome (SS) is a systemic inflammatory disease with immunologic abnormalities characterized by different clinical manifestations, including dry eye, dry mouth, arthralgia, fatigue, leucopenia, glomerulonephritis, and peripheral neuropathy [1]. The two major features are ocular and oral glandular involvement with impaired function of glands. Active lymphocytic infiltration of the salivary and lacrimal glands may be observed from pathologic findings in patients with SS. In the local pathogenesis of different glands, proliferation of B cells, activation of dendritic cells,
and autoreactive T helper 1 and T helper 17 cells develop among the salivary epithelium [2]. Throughout the systemic inflammation, the presentation of proinflammatory cytokines, including interleukin-17 and interferon-γ, are activated [1]. Traditional risk factors for the progression of coronary artery disease (CAD) include age, sex, hypertension, smoking, diabetes, obesity, and hyperlipidemia. Systemic inflammation may also serve as one risk for the development of CAD. Increased risks of CAD have been described in previous studies in other systemic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. SS is also a chronic autoimmune inflammatory disease, which is highly associated with atherosclerosis [3]. Cerebrovascular events and CAD are more common in patients with primary SS when compared with the general population [4]. An increased frequency of high carotid intima-media thickness and arterial stiffness is found in patients with primary SS [5]. Patients with primary SS are at risk of developing subclinical atherosclerosis and arterial stiffness. Rates of anxiety, along with impaired sleep, are higher among patients with SS, and impaired sleep may create a significantly higher risk of subclinical atherosclerosis [6]. Hydroxychloroquine (HCQ) is an antimalarial agent that has been used for the treatment of different autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and SS. The clinical application of HCQ for autoimmune diseases is to control disease activity by immunomodulation. HCQ was one of the first drugs applied in the treatment of SS that resulted in significant improvement of arthritis or fatigue [7]. From a prospective and double-blind study, the medication of HCQ did not improve clinical symptoms of SS significantly without decreasing autoantibodies and high immunoglobulin G levels [8]. However, the duration of this study was 24 weeks of treatment, and further studies are needed to evaluate the longer-term effects of HCQ. Previous studies indicated that the effects of anti-arthrosclerosis medications or those that prevent cardiovascular events (excluding immunosuppressants) may be seen in patients with rheumatoid arthritis and systemic lupus erythematosus [9–12]. Significant decreasing risk of cardiovascular events is observed when patients with autoimmune diseases receive HCQ therapy. However, the level of cardiovascular protection is still not clear in SS patients who use HCQ on a long-term basis. In our study, we evaluated the incidence of CAD in SS patients who are using HCQ long-term.

2. Materials and Methods

2.1. Data Source

We conducted a retrospective cohort study by using the National Health Insurance Research Database (NHIRD), which enrolls almost 99% of the population in Taiwan. The dataset consists of all claims in health care, including medical visits, emergency care, and hospitalization. One million participants were sampled from the 23 million beneficiaries, and data were collected from 2000 to 2012. The data in the NHIRD were encrypted, and this study was approved by the Institutional Review Board of Chung Shan Medical University Hospital.

2.2. Study Population and Exposure

The study population consisted of patients newly diagnosed with SS (ICD-9-CM = 710.2), aged 20 years or more, from 2000 to 2012. Administration of HCQ within one year of diagnosis was necessary for inclusion. A total of 1674 SS patients treated with HCQ were enrolled. To confirm new-onset CAD, we excluded those with CAD diagnosed before the index date. Therefore, 1142 SS patients were included after exclusion for previous CAD. The index date was the first date of usage of HCQ. To perform the adherence of HCQ, we used the medication possession ratio (MPR) that was from 0 to 1. The closer to 1, the higher compliance the patients had with the medication. The MPR was the total HCQ use days from the SS diagnosis to the index date divided by the time of one year. The baseline characteristics were age, gender, hypertension (ICD-9-CM = 401–405), hyperlipidemia (ICD-9-CM = 272.0–272.4), diabetes (ICD-9-CM = 250), chronic obstructive pulmonary disease (ICD-9-CM = 491, 492, 496), and stroke (ICD-9-CM = 430–438). Those comorbidities were
were followed up with until the occurrence of CAD, the date of 31 December 2013 was reached, and patients is shown in Figure 1. The total number of SS patients was 1142 after follow-up for more than one year. The study flow chart to identify these SS patients was shown in Figure 1.

2.3. Outcome

The outcome variable was defined as a diagnosis of CAD (ICD-9-CM = 410–414). Additionally, more than three outpatient visits or a hospitalization due to CAD were required for inclusion. Patients were followed up with until the occurrence of CAD, the date of 31 December 2013 was reached, or withdrawal from the national insurance system, whichever occurred first. The total number of SS patients was 1142 after follow-up for more than one year. The study flow chart to identify these SS patients is shown in Figure 1.

2.4. Statistical Analysis

The Kaplan–Meier analysis was used to estimate the cumulative incidence of CAD across the HCQ groups, and the log-rank test was used to evaluate the significance. The Cox proportional hazard model was used to estimate the hazard ratio (HR) of CAD in relation to HCQ medication and was adjusted for potential confounding variables. We used statistical software SPSS, version 18.0 (SPSS Inc., Chicago, IL, USA). A p value less than 0.05 was considered to indicate significance.
3. Results

3.1. Study Population

The 1142 SS patients were divided into three groups by medication possession ratio (MPR) to evaluate the drug adherence of HCQ. The three groups were shown as: MPR < 0.40 (N = 653), MPR = 0.40–0.69 (N = 215) and MPR ≥ 0.70 (N = 274). Lower prevalence of hyperlipidemia was observed in the MPR ≥ 0.70 group when compared with the MPR < 0.40 group (3.3% vs. 7.8%, p = 0.022). Other chronic comorbidities, including hypertension, diabetes, chronic obstructive pulmonary disease, and stroke, had no significant difference between the three MPR groups. A higher proportion of corticosteroid medication was found in the MPR ≥ 0.70 group when compared with the MPR < 0.40 group (58% vs. 28.8%, p < 0.001). The data are shown in Table 1.

| Total | MPR < 0.40 (N = 653) | MPR = 0.40–0.69 (N = 215) | MPR ≥ 0.70 (N = 274) |
|-------|-----------------------|---------------------------|---------------------|
| Age | n % | n % | n % | n % | n % |
| <40  | 302 26.4 | 178 27.3 | 51 23.7 | 73 26.6 |
| 40–64 | 677 59.3 | 384 58.8 | 131 60.9 | 162 59.1 |
| ≥65  | 163 14.3 | 91 13.9 | 33 15.3 | 39 14.2 |
| Mean ± SD | 49.5 ± 14.5 | 49.4 ± 14.4 | 49.8 ± 15.3 | 49.5 ± 13.9 |
| Gender | 0.891 |  |  |  |
| Female | 997 87.3 | 562 86.1 | 188 87.4 | 247 90.1 |
| Male | 145 12.7 | 91 13.9 | 27 12.6 | 27 9.9 |
| Hypertension | 143 12.5 | 89 13.6 | 29 13.5 | 25 9.1 |
| Hyperlipidemia | 79 6.9 | 51 7.8 | 19 8.8 | 9 3.3 |
| Diabetes | 68 6.0 | 35 5.4 | 19 8.8 | 14 5.1 |
| COPD | 22 1.9 | 15 2.3 | 2 0.9 | 5 1.8 |
| Stroke | 33 2.9 | 16 2.5 | 5 2.3 | 12 4.4 |
| Corticosteroids | 451 39.5 | 159 28.8 | 104 48.4 | 188 58.0 |
| NSAIDs | 787 68.9 | 434 66.5 | 149 69.3 | 204 74.5 |
| p | 0.234 | 0.149 | 0.022 | 0.139 |

MPR: medication possession ratio. COPD: chronic obstructive pulmonary disease. NSAIDs: non-steroidal anti-inflammatory drugs.

3.2. A Higher Incidence of CAD Developed in the SS Patients with a Lower MPR (<0.40) of HCQ, and There Was Significant Decreasing Cumulative Incidence of CAD in the SS Patients with a Higher MPR (≥0.70) of HCQ

Significantly lower HR of CAD was observed in the patients with higher MPR (≥0.70) of HCQ when compared with the patients with lower MPR (<0.40) of HCQ (HR = 0.49, 95% CI: 0.26–0.94), after adjusting for age, comorbidities, and gender (Table 2). At the same time, traditional risk factors for CAD, including old age, hypertension, and hyperlipidemia, with higher HR were also observed (age ≥ 65: HR = 4.69, 95% CI: 1.99–11.03; hypertension: HR = 1.98, 95% CI: 1.17–3.36; hyperlipidemia: HR = 2.27, 95% CI: 1.18–4.38). In our study, SS patients with a comorbidity of chronic obstructive pulmonary disease may have higher HR for incidence of CAD (HR = 3.57, 95% CI: 1.51–8.46). There was no significant increasing risk of CAD with the use of corticosteroids or NSAIDs. The cumulative incidence of CAD was significantly lower in the SS patients with a higher MPR (≥0.70) of HCQ (Figure 2).
Table 2. The attack of coronary artery disease (CAD) in SS patients by different conditions.

|                          | No. of CAD | Observed Person-Years | Incidence Density (Per 1000 Person-Years) | Crude HR | 95% C.I. | Adjusted HR † | 95% C.I. |
|--------------------------|------------|------------------------|------------------------------------------|----------|---------|--------------|---------|
| **MPR of HCQ**           |            |                        |                                          |          |         |              |         |
| <0.40                    | 60         | 653                    | 91.9                                     | 1        |         |              |         |
| 0.40–0.69                | 16         | 215                    | 74.4                                     | 0.88     | 0.51–1.53| 0.93         | 0.53–1.63|
| ≥0.70                    | 12         | 274                    | 43.8                                     | 0.46     | 0.25–0.86| 0.49         | 0.26–0.94|
| **Age**                  |            |                        |                                          |          |         |              |         |
| <40                      | 8          | 1680                   | 4.8                                      | 1        |         |              |         |
| 40–64                    | 53         | 3270                   | 16.2                                     | 3.37     | 1.60–7.10| 2.99         | 1.41–6.35|
| ≥65                      | 27         | 624                    | 43.3                                     | 8.93     | 4.04–19.7| 4.69         | 1.99–11.03|
| **Gender**               |            |                        |                                          |          |         |              |         |
| Female                   | 72         | 4850                   | 14.8                                     | 1        |         |              |         |
| Male                     | 16         | 723                    | 22.1                                     | 1.49     | 0.87–2.57| 1.15         | 0.65–2.05|
| **Hypertension**         |            |                        |                                          |          |         |              |         |
| No                       | 65         | 5071                   | 12.8                                     | 1        |         |              |         |
| Yes                      | 23         | 502                    | 45.8                                     | 3.49     | 2.16–5.65| 1.98         | 1.17–3.36|
| **Hyperlipidemia**       |            |                        |                                          |          |         |              |         |
| No                       | 74         | 5331                   | 13.9                                     | 1        |         |              |         |
| Yes                      | 14         | 242                    | 57.8                                     | 3.96     | 2.22–7.06| 2.27         | 1.18–4.38|
| **Diabetes**             |            |                        |                                          |          |         |              |         |
| No                       | 78         | 5327                   | 14.6                                     | 1        |         |              |         |
| Yes                      | 10         | 246                    | 40.6                                     | 2.70     | 1.39–5.22| 1.41         | 0.69–2.89|
| **COPD**                 |            |                        |                                          |          |         |              |         |
| No                       | 81         | 5470                   | 14.8                                     | 1        |         |              |         |
| Yes                      | 7          | 103                    | 68.0                                     | 4.70     | 2.17–10.18| 3.57         | 1.51–8.46|
| **Stroke**               |            |                        |                                          |          |         |              |         |
| No                       | 83         | 5447                   | 15.2                                     | 1        |         |              |         |
| Yes                      | 5          | 127                    | 39.4                                     | 2.48     | 0.78–6.13| 1.17         | 0.44–3.10|
| **Corticosteroids**      |            |                        |                                          |          |         |              |         |
| No                       | 43         | 2926                   | 14.7                                     | 1        |         |              |         |
| Yes                      | 45         | 2647                   | 17.0                                     | 1.18     | 0.78–1.80| 1.23         | 0.79–1.93|
| **NSAIDs**               |            |                        |                                          |          |         |              |         |
| No                       | 10         | 831                    | 12.0                                     | 1        |         |              |         |
| Yes                      | 78         | 4742                   | 16.4                                     | 1.47     | 0.75–2.86| 1.36         | 0.68–2.70|

MPR: medication possession ratio. Bold font represents statistical significance (p < 0.05). COPD: chronic obstructive pulmonary disease. NSAIDs: non-steroidal anti-inflammatory drugs. † Adjusted for age, gender, hypertension, hyperlipidemia, diabetes, COPD, stroke, corticosteroids and NSAIDs.
was observed in the SS patients aged 40–64. In this group, a significantly lower HR of CAD developed in the patients with SS by different incidence of CAD between a higher and lower MPR of HCQ among the male SS patients. The evaluation of CAD attack of HCQ found in the SS patients with a higher MPR (\( HR = 0.28, 95\% \text{ CI: } 0.12–0.68 \)) of HCQ when compared with a lower MPR (<0.40) of HCQ. However, there was no significant cardiovascular protection between a higher and a lower MPR of HCQ among the male SS patients. The evaluation of CAD attack in patients with SS by different age and gender is shown in Table 3.

3.3. Significant Cardiovascular Protection of HCQ in the 40–64 Age Group among the Patients with SS

When the age of SS patients was less than 40 years or more than 65 years, there was no significantly different incidence of CAD between a higher and lower MPR of HCQ. However, a different condition was observed in the SS patients aged 40–64. In this group, a significantly lower HR of CAD developed in the SS patients with a higher MPR (\( \geq 0.70 \)) of HCQ when compared with a lower MPR (<0.40) of HCQ (HR = 0.28, 95\% CI: 0.12–0.68). Among the female SS patients, a lower HR of CAD was also found in the SS patients with a higher MPR (\( \geq 0.70 \)) of HCQ when compared with a lower MPR (<0.40) of HCQ (HR = 0.36, 95\% CI: 0.16–0.77). However, there was no significant cardiovascular protection between a higher and a lower MPR of HCQ among the male SS patients. The evaluation of CAD attack in the patients with SS by different age and gender is shown in Table 3.

**Figure 2.** The cumulative incidence of CAD in the three groups with significant decreasing cumulative incidence of CAD in the group with higher MPR (\( \geq 0.70 \)) of HCQ.

**Table 3.** The evaluation of CAD attack in patients with SS by different age and gender.

| Age <40 \(^\dagger\) MPR of HCQ | N | No. of CAD | Crude HR | 95\% C.I. | Adjusted HR \(^\dagger\) | 95\% C.I. |
|---------------------------------|---|------------|----------|-----------|-----------------|-----------|
| <0.40                           | 178| 7          | 1        | 0.06–3.88 | 0.40            | 0.05–3.49 |
| 0.40–0.69                       | 51 | 1          | 0.48     | NA        | NA              | NA        |
| \( \geq 0.70 \)                 | 73 | 0          | NA       | NA        | NA              | NA        |

| Age \( \leq 40–64 \) \(^\dagger\) MPR of HCQ | N | No. of CAD | Crude HR | 95\% C.I. | Adjusted HR \(^\dagger\) | 95\% C.I. |
|-----------------------------------------------|---|------------|----------|-----------|-----------------|-----------|
| <0.40                                         | 384| 39         | 1        | 0.31–1.40 | 0.58            | 0.27–1.25 |
| 0.40–0.69                                     | 131| 8          | 0.65     | 0.14–0.79 | 0.28            | 0.12–0.68 |
| \( \geq 0.70 \)                              | 162| 6          | 0.34     | NA        | NA              | NA        |

| Age \( \geq 65 \) \(^\dagger\) MPR of HCQ | N | No. of CAD | Crude HR | 95\% C.I. | Adjusted HR \(^\dagger\) | 95\% C.I. |
|-------------------------------------------|---|------------|----------|-----------|-----------------|-----------|
| <0.40                                      | 91 | 14         | 1        | 0.67–4.15 | 1.84            | 0.71–4.73 |
| 0.40–0.69                                  | 33 | 7          | 1.67     | 0.52–3.59 | 1.46            | 0.52–4.13 |
| \( \geq 0.70 \)                           | 39 | 6          | 1.37     | NA        | NA              | NA        |
Table 3. Cont.

|                       | N  | No. of CAD | Crude HR | 95% C.I. | Adjusted HR † | 95% C.I. |
|-----------------------|----|------------|----------|----------|---------------|----------|
| **Female ‡**          |    |            |          |          |               |          |
| MPR of HCQ <0.40      | 562| 49         | 1        |          | 1             |          |
| 0.40–0.69             | 188| 15         | 1.03     | 0.58–1.84| 0.99          | 0.55–1.80|
| ≥0.70                 | 247| 8          | 0.37     | 0.17–0.77| 0.36          | 0.16–0.77|
| **Male ‡**            |    |            |          |          |               |          |
| MPR of HCQ <0.40      | 91 | 11         | 1        |          | 1             |          |
| 0.40–0.69             | 27 | 1          | 0.24     | 0.03–1.91| 0.30          | 0.03–2.80|
| ≥0.70                 | 27 | 4          | 1.06     | 0.34–3.36| 0.85          | 0.22–3.20|

NA: not applicable. MPR: medication possession ratio. † Adjusted for gender, diabetes, corticosteroids and NSAIDs. ‡ Adjusted for age, hypertension, hyperlipidemia, diabetes, COPD, stroke, corticosteroids and NSAIDs.

4. Discussion

In our study, a higher incidence of CAD was found in the SS patients with a lower MPR of HCQ, and the incidence was decreased in the SS patients with a higher MPR of HCQ. The cumulative incidence of CAD was significantly lower in the SS patients with a higher MPR of HCQ when compared with SS patients with a lower MPR of HCQ. The risk factors for CAD, including old age, hypertension, hyperlipidemia, and COPD, were observed in our data.

SS is a chronic systemic autoimmune disease, and different extraglandular features may develop during the disease progression. Areas involved include skin, thyroid gland, lungs, and the musculoskeletal systems. The cardiovascular system is one of the major areas for extraglandular manifestations. Patients with primary SS have a higher cardiovascular involvement rate than that of the controls [4]. Subclinical atherosclerosis, myocardial infarction, venous thromboembolism, hypertension, and hyperlipidemia can develop in the cardiovascular system. Cerebrovascular events and myocardial infarction are more common among the primary SS patients [13]. The presentation of extraglandular manifestations is associated with an increased comorbidity burden, and cardiovascular disease is one of major associations [14]. Persistent endothelial dysfunction-related subclinical atherosclerosis may be found in SS patients with elevation of endothelial microparticles and endothelial progenitor cells [15]. The prevalence of valvular regurgitation, pericardial effusion, and pulmonary hypertension is higher in SS patients with correlations of immunologic abnormality [16]. Our study showed that hyperlipidemia, hypertension, and COPD may serve as higher risks for the progression of CAD. Among patients with SS, a significantly higher prevalence of hypertension or hyperlipidemia is observed when compared with that in the general population [13,17]. During the disease course of SS, different medications, including glucocorticoids, NSAIDs, and immunosuppressive agents may be used to control the disease activity. NSAIDs may be associated with an increased risk of cardiovascular events in patients with SS [18]. However, in our study, there was no significant difference when using NSAIDs or glucocorticoids. Higher glucocorticoid exposure is associated with CAD risk increase, but minimizing glucocorticoid use may improve CV outcomes in patients with rheumatoid arthritis due to under control of disease activity [19]. The patients with SS usually receive a lower dosage of glucocorticoid when compared with rheumatoid arthritis or systemic lupus erythematosus patients. Adequate control of SS patients’ related systemic inflammations by glucocorticoids may explain this phenomenon. Rheumatoid arthritis is another systemic inflammation autoimmune disease and chronic inflammation may serve as one of the risk factors for the progression of CVD. Aggressive control of the disease activity of rheumatoid arthritis can be achieved by adequate medication with methotrexate, and the systemic inflammation is improved. Methotrexate and biologics use was associated with CVD risk reduction in an observational study [19]. Therefore, high risk of cardiovascular events in
SS patients may be associated with long disease duration, more severe disease activity with active immunologic or clinical features, and the agent to control disease activity.

HCQ is a traditional immunosuppressive drug used for different autoimmune diseases. Except for the effects of immunomodulation, multiple efficacies, including protection against the progression of diabetes, thrombotic events, and dyslipidemia, have been reported in previous studies [4,20–22]. A lower percentage of hyperlipidemia was observed in the MPR ≥ 0.70 group when compared with the MPR < 0.40 group (3.3% vs. 7.8%, p = 0.022) in our study (Table 1). Previous studies have indicated that a longer duration of HCQ use is associated with better lipid profiles in patients with rheumatoid arthritis [23]. SS is a chronic inflammation-related autoimmune disease, and a higher prevalence of subclinical atherosclerosis may be associated with this autoimmune dysregulation-related systemic inflammation [3]. Endothelial dysfunction and damage-related impaired vasodilatation play major roles in atherosclerosis pathogenesis. HCQ may prevent endothelial dysfunction in the mouse model of antiphospholipid syndrome [24]. HCQ can modulate the production of proinflammatory cytokines, the activation of toll-like receptor and leukocyte generation of reactive oxygen species [25]. These inflammatory-related progressions may serve as important in the development of atherosclerosis in cardiovascular diseases. Adequate control of disease activity and systemic inflammation can improve the incidence of subclinical atherosclerosis. In our study, relatively good drug adherence to HCQ and corticosteroids was found in the MPR ≥ 0.70 group. SS-related systemic inflammation may be regulated by these immunosuppressive therapies. Therefore, a significant decreasing cumulative incidence of CAD was found in the higher MPR (≥0.70) of the HCQ group (Figure 2). Male gender is one of the risk factors for developing CAD, although our study showed that there was no significant difference in incidence between males and females. This condition may be due to a lower percentage of males (13%) in our study. Therefore, significantly lower incidence of CAD was found in the group of female SS patients with higher MPR (≥0.70) of HCQ when compared with the lower MPR (<0.40) of HCQ group (HR = 0.36, 95% CI: 0.16–0.77). This significant difference could not be observed among the male SS patients and this condition may be due to the small number of males in our study. However, the clinical symptoms of SS, including dry eye, dry mouth and arthralgia, are usually found among the patients with IgG4-related disease (IgG4-RD) [26]. Abnormal serum studies including hypergammaglobulinemia, hypocomplementemia, and autoantibodies are also observed. IgG4-RD typically affects middle aged and older men [27]. In clinical practice, this is difficult to distinguish from SS and IgG4-RD. This may be another reason why there was no significant difference in elderly men. The limitations of this study were as follows: first, primary and secondary SS were both included in this study; second, MPR was used to evaluate the drug adherence of HCQ, but irregular medication was usually found in SS patients; and third, most SS patients were female.

5. Conclusions

In summary, HCQ may be used to control the clinical manifestations of SS. HCQ has a wide range of positive effects including immunomodulation or immunosuppression. Significant cardiovascular protection of long-term HCQ therapy was observed from our findings. Therefore, adequate immunotherapy of HCQ is suggested in the patients with SS.

Author Contributions: D.-H.Y., L.-F.P., Y.-H.W. and J.C.-C.W. conceptualized and designed the study. D.-H.Y. did most of the writing of the manuscript. Y.-H.W. and L.-F.P. collected and analyzed the data. J.C.-C.W. contributed to improve the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Taichung Armed-Forces General Hospital (Grant no: 106B01 and 106A02) and received assistance of the Department of Medical Education and Research, Taichung Armed Forces General Hospital.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Mariette, X.; Criswell, L.A. Primary Sjogren’s Syndrome. *N. Engl. J. Med.* **2018**, *378*, 931–939. [CrossRef] [PubMed]
2. Alunno, A.; Leone, M.C.; Giacomelli, R.; Gerli, R.; Carubbi, F. Lymphoma and Lymphomagenesis in Primary Sjogren’s Syndrome. *Front. Med.* **2018**, *5*, 102. [CrossRef] [PubMed]
3. Bartoloni, E.; Alunno, A.; Valentini, V.; Valentini, E.; La Paglia, G.C.M.; Leone, M.C.; Caffaro, G.; Marcucci, E.; Bonifacio, A.F.; Luccioli, F.; et al. The prevalence and relevance of traditional cardiovascular risk factors in primary Sjogren’s syndrome. *Clin. Exp. Rheumatol.* **2018**, *36* (Suppl. 112), 113–120. [PubMed]
4. Perez-De-Lis, M.; Akasbi, M.; Siso, A.; Diez-Cascon, P.; Brito-Zeron, P.; Diaz-Lagares, C.; Ortiz, J.; Perez-Alvarez, R.; Ramos-Casals, M.; Coca, A. Cardiovascular risk factors in primary Sjogren’s syndrome: A case-control study in 624 patients. *Lupus* **2010**, *19*, 941–948. [CrossRef] [PubMed]
5. Yong, W.C.; Sanguankeo, A.; Upala, S. Association between primary Sjogren’s syndrome, arterial stiffness, and subclinical atherosclerosis: A systematic review and meta-analysis. *Clin. Rheumatol.* **2019**, *38*, 447–455. [CrossRef]
6. Tully, P.J.; Harrison, N.J.; Cheung, P.; Cosh, S. Anxiety and Cardiovascular Disease Risk: A Review. *Curr. Cardiol. Rep.* **2016**, *18*, 120. [CrossRef]
7. Wang, S.Q.; Zhang, L.W.; Wei, P.; Hua, H. Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: A systematic review and meta-analysis. *BMC Musculoskelet. Disord.* **2017**, *18*, 186. [CrossRef]
8. Gottenberg, J.E.; Ravaud, P.; Puéchal, X.; Le Guern, V.; Sibilia, J.; Goeb, V.; Larroche, C.; Dubost, J.J.; Rist, S.; Saraux, A.; et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: The JOQUER randomized clinical trial. *JAMA* **2014**, *312*, 249–258. [CrossRef]
9. Ammirati, E.; Bozzolo, E.P.; Contri, R.; Baragetti, A.; Palini, A.G.; Cianflone, D.; Banfi, M.; Uboldi, P.; Bottini, G.; Scotti, I.; et al. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. *Nutr. Metab. Cardiovasc. Dis.* **2014**, *24*, 751–759. [CrossRef]
10. Yang, D.H.; Leong, P.Y.; Sia, S.K.; Wang, Y.H.; Wei, J.C.C. Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus. *J. Clin. Med.* **2019**, *8*, 796. [CrossRef] [PubMed]
11. Rempenault, C.; Combe, B.; Barnetche, T.; Gaujoux-Viala, C.; Lukas, C.; Morel, J.; Hua, C. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: A systematic review and meta-analysis. *Ann. Rheum. Dis.* **2018**, *77*, 98–103. [CrossRef]
12. Cai, X.; Luo, J.; Wei, T.; Qin, W.; Li, X.; Wang, X. Risk of Cardiovascular Involvement in Patients with Primary Sjogren’s Syndrome: A large-scale cross-sectional cohort study. *Acta Reumatol. Port.* **2019**, *44*, 71–77.
13. Bartoloni, E.; Baldini, C.; Schilacci, G.; Quartuccio, L.; Priori, R.; Carubbi, F.; Bini, V.; Alunno, A.; Bombardieri, S.; De Vita, S.; et al. Cardiovascular disease risk burden in primary Sjogren’s syndrome: Results of a population-based multicentre cohort study. *J. Intern. Med.* **2015**, *278*, 185–192. [CrossRef]
14. Zhang, Y.; Li, M.; Zhang, L.; Li, Q.; Yang, P.; Kong, X.; Duan, X.; Zhang, M.; Li, X.; Wang, Y.; et al. Association between comorbidities and extraglandular manifestations in primary Sjogren’s syndrome: A multicenter cross-sectional study. *Clin. Rheumatol.* **2020**, *39*, 2677–2688. [PubMed]
15. Bartoloni, E.; Alunno, A.; Bistoni, O.; Caterbi, S.; Luccioli, F.; Santoboni, G.; Mirabelli, G.; Cannarile, F.; Gerli, R. Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjogren’s syndrome: New markers of chronic endothelial damage? *Rheumatology* **2015**, *54*, 536–544. [PubMed]
16. Vassiliou, V.A.; Moysakis, I.; Boki, K.A.; Moutsopoulos, H.M. Is the heart affected in primary Sjogren’s syndrome? An echocardiographic study. *Clin. Exp. Rheumatol.* **2008**, *26*, 109–112. [PubMed]
17. Gerli, R.; Bartoloni Bocci, E.; Vaudo, G.; Marchesi, S.; Vitali, C.; Shoenfeld, Y. Traditional cardiovascular risk factors in primary Sjogren’s syndrome—role of dyslipidaemia. *Rheumatology* **2008**, *45*, 1580–1581. [CrossRef]
18. Patrono, C. Cardiovascular effects of cyclooxygenase-2 inhibitors: A mechanistic and clinical perspective. *Br. J. Clin. Pharmacol.* **2016**, *82*, 957–964. [CrossRef]
19. Ozen, G.; Pedro, S.; Michaud, K. The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. *J. Rheumatol.* **2020**. [CrossRef]
20. Miranda, S.; Billoir, P.; Damian, L.; Thiebaut, P.A.; Schapman, D.; Le Besnerais, M.; Jouen, F.; Galas, L.; Levesque, H.; Le Cam-Duchez, V.; et al. Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. *PLoS ONE* 2019, 14, e0212614. [CrossRef]

21. Chen, Y.M.; Lin, C.H.; Lan, T.H.; Chen, H.H.; Chang, S.N.; Chen, Y.H.; Wang, J.S.; Hung, W.T.; Lan, J.L.; Chen, D.Y. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: A population-based cohort study. *Rheumatology* 2015, 54, 1244–1249. [CrossRef] [PubMed]

22. Morris, S.J.; Wasko, M.C.M.; Antohe, J.L.; Sartorius, J.A.; Kirchner, H.L.; Dancea, S.; Bili, A. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. *Arthritis Care Res.* 2011, 63, 530–534. [CrossRef] [PubMed]

23. Kerr, G.; Aujero, M.; Richards, J.; Sayles, H.; Davis, L.; Cannon, G.; Caplan, L.; Michaud, K.; Mikuls, T. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: Pharmacologic implications. *Arthritis Care Res.* 2014, 66, 1619–1626. [CrossRef]

24. Urbanski, G.; Caillon, A.; Poli, C.; Kauffenstein, G.; Begorre, M.A.; Loufrani, L.; Henrion, D.; Belizna, C. Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome. *PLoS ONE* 2018, 13, e0206814. [CrossRef] [PubMed]

25. Rainsford, K.D.; Parke, A.L.; Clifford-Rashotte, M.; Kean, W.F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. *Inflammopharmacology* 2015, 23, 231–269. [CrossRef] [PubMed]

26. Fragoulis, G.E.; Zampeli, E.; Moutsopoulos, H.M. IgG4-related sialadenitis and Sjogren’s syndrome. *Oral Dis.* 2017, 23, 152–156. [CrossRef] [PubMed]

27. Lanzillotta, M.; Mancuso, G.; Della-Torre, E. Advances in the diagnosis and management of IgG4 related disease. *BMJ* 2020, 369, m1067. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).